Overview


According to FutureWise analysis, the market for Achondrogenesis is expected to grow at a CAGR of 4.32% over the forecast period of 2023-2031.

Achondrogenesis is a group of rare skeletal disorders that affects the development of cartilage and bones. These conditions are characterized by a small body, short limbs, and other skeletal anomalies. The conditions are life-threatening, and most affected infants are either stillborn or pass away shortly after birth due to respiratory failure. There are three types of achondrogenesis genetic conditions; type IA and type IB are autosomal recessive disorders, whereas achondrogenesis type II is an autosomal dominant disorder. All types of achondrogenesis are very severe skeletal dysplasias and are detected by prenatal ultrasound examination as early as week 14-17 of gestational age. Genetic mutations cause achondrogenesis, where each type of achondrogenesis is associated with a specific mutation. Mutations inherited from both parents induce Type 1A and 1B, whereas Type 2 results from new mutations arising at conception in infants with no prior family history of the disorder.

Achondrogenesis is categorized into three main types (1A, 1B, and 2), each with slightly different signs, symptoms, inheritance patterns, and genetic causes. Achondrogenesis type 1A, also known as the Houston-Harris type, is the least well-understood of the three types. Infants affected by this type have extremely short limbs, a narrow chest, easily fractured short ribs, and a deficiency in normal bone formation (ossification) in the skull, spine, and pelvis. Achondrogenesis type 1B, the Parenti-Fraccaro type, is characterized by exceptionally short limbs, a narrow chest, and a rounded abdomen. The fingers and toes tend to be short, and the feet may exhibit inward and upward (clubfeet). Also, affected infants frequently have a soft out-pouching around the belly button (an umbilical hernia) or near the groin (an inguinal hernia). Infants with achondrogenesis type 2, also referred to as the Langer-Saldino type, usually have brief arms and legs, a slender chest with short ribs, and underdeveloped lungs. This condition is also associated with a deficiency in the spine and pelvis ossification. Distinctive facial features like a small chin, a prominent forehead, and, in some, an opening in the top of the mouth (a cleft palate).

FutureWise Market Research has published a report that provides an insightful analysis achondrogenesis market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry.

According to the analysis conducted by FutureWise research analysts, achondrogenesis market is estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.

  • Cook
  • Thermo Fisher Scientific
  • CooperSurgical
  • Illumina
  • Siemens
  • FUJIFILM Holdings
  • Koninklijke
  • Philips
  • Stryker
  • Toshiba Corporation
  • Invivoscribe
  • Abbott Molecular
  • INVITROGEN CORPORATION
  • Roche Molecular Systems

(Note: The list of the major players will be updated with the latest market scenario and trends)

The increasing prevalence of achondrogenesis cases within clinical settings is anticipated to significantly drive the growth of the achondrogenesis market during the forecast period. This is attributed to increased awareness, improved diagnostic capacities, and advancements in genetic research, leading to earlier and more accurate diagnoses. As healthcare providers become increasingly proficient at identifying achondrogenesis, there is a growing demand to develop and invest in novel treatments, potentially addressing the unmet medical needs of affected individuals. Moreover, the growing patient population may promote collaborative efforts between researchers, pharmaceutical companies, and medical advocacy groups, facilitating innovation and progress toward effective treatments. Therefore, boosting the market growth. However, obtaining regulatory approval for the potential treatments targeting achondrogenesis poses a substantial hurdle to market growth. The stringent evaluation process required by regulatory authorities demands comprehensive clinical evidence demonstrating both safety and efficacy and often requires substantial investment and resource-intensive clinical trials. Furthermore, due to the rarity of achondrogenesis, recruiting sufficient participants for these trials might be challenging, leading to delays and complications. Even with active efforts, there is no assurance of success, as regulatory decisions hinge on the complete assessment of the treatment's risk-benefit. This prolonged approval process may deter pharmaceutical companies from investing in research and development for achondrogenesis, limiting the availability of possible treatment options for affected individuals and further hindering the target market over the projection period.

By Type

  • Achondrogenesis type IA
  • Achondrogenesis type IB
  • Achondrogenesis type II

By Application

  • Hospital and Clinics
  • Diagnostic centers
  • Research and Academic Institutes
  • Other

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered highest share in the market in 2022. Due to factors such as the rise in awareness among individuals, rising healthcare expenditure, increasing research activities, and large dependence of patients on supportive care and palliative care, new market initiatives, presence of market players, and technological advancements for disease diagnosis are expected to fuel the market growth during the forecast period. Additionally, increased clinical diagnostic activities, collaborations, and distribution network development in the US will likely propel the target market. For instance, in November 2022, Illumina Inc. and Genetic Alliance launched a global initiative with an investment of $120 Million. This aims to increase equity and improve outcomes for families impacted by genetic disease. Therefore, propelling the market growth over the projection period in the area.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Achondrogenesis Market By Type, By Application and By Region.
  • To cater comprehensive insights on factors such as drivers, restraints, trends, opportunity, and additionally segmental and regional factors impacting market growth.
  • To evaluate current market trends and forecast micro-markets and the overall market projections which are represented in the format of data-sets and ppt.
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa. 
  • To provide information on competitors which includes landscape mapping, technological advancements, R&D spending, news concerning strategic alliances, and new product launches

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

 

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1 . Years Considered for the Study
         3.2 . Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1 . Secondary Data
          1.1.1 . Key Data from Secondary Sources
         1.2 . Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.  Achondrogenesis Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Achondrogenesis Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.  Achondrogenesis Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals and Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies

  • 7.  Achondrogenesis Market, By Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Achondrogenesis type IA
        2. Achondrogenesis type IB
        3. Achondrogenesis type II

  • 8.  Achondrogenesis Market, By Application Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospital and Clinics
        2. Diagnostic centers
        3. Research and Academic Institutes
        4. Other

  • 9.   North America Achondrogenesis Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 10.   Latin America Achondrogenesis Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 11.   Europe Achondrogenesis Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 12.   Asia Pacific Achondrogenesis Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 13.   Middle East and Africa Achondrogenesis Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Saudi Arabia
         2.2. UAE
         2.3. South Africa
         2.4. Egypt
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 14.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 15.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Cook
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Thermo Fisher Scientific
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Cooper Surgical
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Illumina
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Siemens
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Fujifilm Holdings
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Koninklijke
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Philips
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Stryker
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Toshiba Corporation
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. Invivoscribe
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
        12. Abbott Molecular
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview
        13. Invitrogen Corporation
         13.1. Company Overview
         13.2. Product Portfolio
         13.3. SWOT Analysis
         13.4. Financial Overview
         13.5. Strategic Overview
        14. Roche Molecular Systems
         14.1. Company Overview
         14.2. Product Portfolio
         14.3. SWOT Analysis
         14.4. Financial Overview
         14.5. Strategic Overview
  • 16.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 17.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients